# US 2003/0069313 A1 · Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069313 A1
- Document ID: US20030069313A1
- Status: Published application
- Kind: A1
- Application number: 10/283,573
- Filed: 2002-10-30
- Published: 2003-04-10
- Earliest claimed: 1999-08-16
- Assignees: Cephalon, Inc.
- Inventors: Matthew S. Miller; Thomas E. Scammell
- Web page: https://patentgrep.com/patent/US20030069313A1

## CPC

- G01N 33/5088: {of vertebrates}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.

## Claims

### Claim 1

A method of treating attention deficit hyperactivity disorder comprising administering to a subject suffering from or susceptible to the development of attention deficit hyperactivity disorder a composition comprising a modafinil compound in an amount effective to improve or prevent symptoms of attention deficit hyperactivity disorder in said subject.

### Claim 2

A method of treating fatigue associated with multiple sclerosis comprising administering to a subject suffering from multiple sclerosis fatigue a composition comprising a modafinil compound in an amount effective to improve or prevent symptoms of multiple sclerosis fatigue in said subject.

### Claim 3

A method of treating a subject suffering from the symptoms of attention deficit hyperactivity disorder or multiple sclerosis fatigue comprising administering to said subject a pharmaceutical composition comprising a modafinil compound in an amount effective to stimulate activity in the tuberomamillary neurons of the brain of said subject.

### Claim 4

A pharmaceutical composition in unit dose form, for use in treating attention deficit hyperactivity disorder in a subject susceptible to the development of or suffering from attention deficit hyperactivity disorder, which comprises:
an amount of a modafinil compound such that one or more unit doses thereof are effective to stabilize or improve the symptoms of attention deficit hyperactivity disorder in said subject upon periodic administration.

### Claim 5

A pharmaceutical composition in unit dose form, for use in treating fatigue in a multiple sclerosis patient, which comprises:
an amount of a modafinil compound such that one or more unit doses thereof are effective to stabilize or improve the symptoms of multiple sclerosis fatigue in said patient upon periodic administration.

### Claim 6 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said modafinil compound is modafinil.

### Claim 7 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said subject is an adult human.

### Claim 8 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said subject is a human child.

### Claim 9 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said effective amount is from about 1 to about 400 mg per daily dose.

### Claim 10 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said effective amount is from about 100 to about 400 mg per daily dose.

### Claim 11 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said effective amount is from about 200 to about 400 mg per daily dose.

### Claim 12 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said effective amount is about 200 mg per daily dose.

### Claim 13 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said composition comprising a modafinil compound is formulated for oral administration.

### Claim 14 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein said composition comprising a modafinil compound is formulated as a tablet.

### Claim 15 (depends on 14)

The method of claim 14, wherein said tablet contains lactose, corn starch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination.

### Claim 16 (depends on 4, 5)

The composition of claim 4 or 5, wherein said modafinil compound is modafinil.

### Claim 17 (depends on 4, 5)

The composition of claim 4 or 5, wherein said subject is an adult human or a human child.

### Claim 18 (depends on 4, 5)

The composition of claim 4 or 5, wherein said effective amount is from about 1 to about 400 mg per daily dose.

### Claim 19 (depends on 4, 5)

The composition of claim 4 or 5, wherein said effective amount is from about 100 to about 400 mg per daily dose.

### Claim 20 (depends on 4, 5)

The composition of claim 4 or 5, wherein said effective amount is from about 200 to about 400 mg per daily dose.

### Claim 21 (depends on 4, 5)

The composition of claim 4 or 5, wherein said effective amount is about 200 mg per daily dose.

### Claim 22 (depends on 4, 5)

The composition of claim 4 or 5, wherein said composition comprising a modafinil compound is formulated for oral administration.

### Claim 23 (depends on 4, 5)

The composition of claim 4 or 5, wherein said composition comprising a modafinil compound is formulated as a tablet.

### Claim 24 (depends on 4, 5)

The composition of claim 4 or 5, wherein said tablet contains lactose, corn starch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination.

### Claim 25

A therapeutic package for dispensing to, or for use in dispensing to, a mammal being treated for attention deficit hyperactivity disorder, comprising:
(1) one or more unit doses, each such unit dose containing an amount of a modafinil compound such that said one or more unit doses thereof are effective to stabilize or improve a symptom of attention deficit hyperactivity disorder in said mammal upon periodic administration and the unit doses being administered periodically; and
(2) a finished pharmaceutical container therefor,
said container containing said unit dose or unit doses and labeling directing the use of said package in the treatment of said mammal.

### Claim 26 (depends on 25)

The therapeutic package according to claim 25 wherein the unit dose is adapted for oral administration.

### Claim 27

A therapeutic package for dispensing to, or for use in dispensing to, a mammal being treated for multiple sclerosis fatigue, comprising:
(1) one or more unit doses, each such unit dose containing an amount of a modafinil compound such that said one or more unit doses thereof are effective to stabilize or improve a symptom of multiple sclerosis fatigue in said mammal upon periodic administration and the unit doses being administered periodically; and
(2) a finished pharmaceutical container therefor,
said container containing said unit dose or unit doses and labeling directing the use of said package in the treatment of said mammal.

### Claim 28 (depends on 27)

The therapeutic package according to claim 27 wherein the unit dose is adapted for oral administration.

### Claim 29

A method of identifying a compound that selectively modulates activity of the tuberomamillary nucleus of the posterior hypothalamus comprising the steps of:
(a) contacting a tuberomamillary nucleus with a test compound; and
(b) determining activity of said tuberomamillary nucleus,
wherein a change in activity of the neurons of said nucleus is indicative of a modulator.

### Claim 30 (depends on 29)

The method of claim 29 wherein said activity is determined by monitoring c-fos levels in said neurons.

### Claim 31 (depends on 29)

A compound identified by method of claim 29.

### Claim 32 (depends on 31)

A method of treating a subject suffering from, or susceptible to excessive daytime sleepiness, attention deficit/hyperactivity disorder, or fatigue associated with multiple sclerosis, comprising administering to said subject an effective amount of a compound of claim 31.
